Cargando…
Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors
Due to its role in lipid biosynthesis, choline kinase α1 (CKα1) is an interesting target for the development of new antitumor agents. In this work, we present a series of 41 compounds designed based on the well-known and successful strategy of introducing thienopyridine and pyrimidine as bioisostere...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032693/ https://www.ncbi.nlm.nih.gov/pubmed/35456549 http://dx.doi.org/10.3390/pharmaceutics14040715 |
_version_ | 1784692707596173312 |
---|---|
author | Luque-Navarro, Pilar María Mariotto, Elena Ballarotto, Marco Rubbini, Gianluca Aguilar-Troyano, Francisco José Fasiolo, Alberto Torretta, Archimede Parisini, Emilio Macchiarulo, Antonio Laso, Alejandro Marco, Carmen Viola, Giampietro Carrasco-Jimenez, María Paz López-Cara, Luisa Carlota |
author_facet | Luque-Navarro, Pilar María Mariotto, Elena Ballarotto, Marco Rubbini, Gianluca Aguilar-Troyano, Francisco José Fasiolo, Alberto Torretta, Archimede Parisini, Emilio Macchiarulo, Antonio Laso, Alejandro Marco, Carmen Viola, Giampietro Carrasco-Jimenez, María Paz López-Cara, Luisa Carlota |
author_sort | Luque-Navarro, Pilar María |
collection | PubMed |
description | Due to its role in lipid biosynthesis, choline kinase α1 (CKα1) is an interesting target for the development of new antitumor agents. In this work, we present a series of 41 compounds designed based on the well-known and successful strategy of introducing thienopyridine and pyrimidine as bioisosteres of other heterocycles in active antitumor compounds. Notwithstanding the fact that some of these compounds do not show significant enzymatic inhibition, others, in contrast, feature substantially improved enzymatic and antiproliferative inhibition values. This is also confirmed by docking analysis, whereby compounds with longer linkers and thienopyrimidine cationic head have been identified as the most compelling. Among the best compounds is Ff-35, which inhibits the growth of different tumor cells at submicromolar concentrations. Moreover, Ff-35 is more potent in inhibiting CKα1 than other previous biscationic derivatives. Treatment of A549, Hela, and MDA-MB-231 cells with Ff-35 results in their arrest at the G1 phase of the cell cycle. Furthermore, the compound induces cellular apoptosis in a concentration-dependent manner. Altogether, these findings indicate that Ff-35 is a promising new chemotherapeutic agent with encouraging preclinical potential. |
format | Online Article Text |
id | pubmed-9032693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90326932022-04-23 Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors Luque-Navarro, Pilar María Mariotto, Elena Ballarotto, Marco Rubbini, Gianluca Aguilar-Troyano, Francisco José Fasiolo, Alberto Torretta, Archimede Parisini, Emilio Macchiarulo, Antonio Laso, Alejandro Marco, Carmen Viola, Giampietro Carrasco-Jimenez, María Paz López-Cara, Luisa Carlota Pharmaceutics Article Due to its role in lipid biosynthesis, choline kinase α1 (CKα1) is an interesting target for the development of new antitumor agents. In this work, we present a series of 41 compounds designed based on the well-known and successful strategy of introducing thienopyridine and pyrimidine as bioisosteres of other heterocycles in active antitumor compounds. Notwithstanding the fact that some of these compounds do not show significant enzymatic inhibition, others, in contrast, feature substantially improved enzymatic and antiproliferative inhibition values. This is also confirmed by docking analysis, whereby compounds with longer linkers and thienopyrimidine cationic head have been identified as the most compelling. Among the best compounds is Ff-35, which inhibits the growth of different tumor cells at submicromolar concentrations. Moreover, Ff-35 is more potent in inhibiting CKα1 than other previous biscationic derivatives. Treatment of A549, Hela, and MDA-MB-231 cells with Ff-35 results in their arrest at the G1 phase of the cell cycle. Furthermore, the compound induces cellular apoptosis in a concentration-dependent manner. Altogether, these findings indicate that Ff-35 is a promising new chemotherapeutic agent with encouraging preclinical potential. MDPI 2022-03-27 /pmc/articles/PMC9032693/ /pubmed/35456549 http://dx.doi.org/10.3390/pharmaceutics14040715 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Luque-Navarro, Pilar María Mariotto, Elena Ballarotto, Marco Rubbini, Gianluca Aguilar-Troyano, Francisco José Fasiolo, Alberto Torretta, Archimede Parisini, Emilio Macchiarulo, Antonio Laso, Alejandro Marco, Carmen Viola, Giampietro Carrasco-Jimenez, María Paz López-Cara, Luisa Carlota Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors |
title | Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors |
title_full | Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors |
title_fullStr | Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors |
title_full_unstemmed | Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors |
title_short | Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors |
title_sort | biological evaluation of new thienopyridinium and thienopyrimidinium derivatives as human choline kinase inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032693/ https://www.ncbi.nlm.nih.gov/pubmed/35456549 http://dx.doi.org/10.3390/pharmaceutics14040715 |
work_keys_str_mv | AT luquenavarropilarmaria biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT mariottoelena biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT ballarottomarco biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT rubbinigianluca biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT aguilartroyanofranciscojose biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT fasioloalberto biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT torrettaarchimede biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT parisiniemilio biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT macchiaruloantonio biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT lasoalejandro biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT marcocarmen biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT violagiampietro biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT carrascojimenezmariapaz biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors AT lopezcaraluisacarlota biologicalevaluationofnewthienopyridiniumandthienopyrimidiniumderivativesashumancholinekinaseinhibitors |